about
Cancer classification using the Immunoscore: a worldwide task forcehMMS2 serves a redundant role in human PCNA polyubiquitinationGuidelines for the use and interpretation of assays for monitoring autophagyHypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein responseGene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control.Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha.Towards the introduction of the 'Immunoscore' in the classification of malignant tumoursMATE2 Expression Is Associated with Cancer Cell Response to MetforminA simple but highly effective approach to evaluate the prognostic performance of gene expression signaturesHotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands.Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine.Lysine 63-polyubiquitination guards against translesion synthesis-induced mutations.Regulation of PCNA polyubiquitination in human cells.Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells.The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5.Apoptosis, p53, and tumor cell sensitivity to anticancer agents.Metabolic targeting of HIF-dependent glycolysis reduces lactate, increases oxygen consumption and enhances response to high-dose single-fraction radiotherapy in hypoxic solid tumors.NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data.Apoptosis: mediator or mode of cell killing by anticancer agents?Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.Hypoxia as a target for combined modality treatments.Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.Modulation of cell death in the tumor microenvironment.RNF8-independent Lys63 poly-ubiquitylation prevents genomic instability in response to replication-associated DNA damage.Tumor-specific gene delivery using genetically engineered bacteria.Cell surface profiling using high-throughput flow cytometry: a platform for biomarker discovery and analysis of cellular heterogeneity.Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.MK3 modulation affects BMI1-dependent and independent cell cycle check-points.Low-dose hyper-radiosensitivity: a consequence of ineffective cell cycle arrest of radiation-damaged G2-phase cells.Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagyTargeting hypoxia tolerance in cancer.Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.Cytotoxic effect of RB 6145 in human tumour cell lines: dependence on hypoxia, extra- and intracellular pH and drug uptakeIndependent and functional validation of a multi-tumour-type proliferation signature.Control of the hypoxic response through regulation of mRNA translation.Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan."Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways.Translational control of gene expression during hypoxia.Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies.Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression.
P50
Q21245495-D8FBD4F7-47C4-41A8-8F7F-1CECC362BA89Q21262982-63962765-4559-4C13-84A7-A5E48521D256Q21996341-378233FD-C5D3-4961-9470-F8269B5A1199Q22000747-C985F55A-71AB-4B99-8801-7E5994E90972Q24304179-655D3299-EAA8-450A-9A1E-B99CBBC63B07Q24540258-82C49FED-D3B8-496F-A771-368EC6498047Q27026489-C021F991-739A-4AFA-B126-B251D3330F34Q28555000-083D7A86-4E11-48D4-9913-0879238A23EFQ28741755-BEFD41FF-30AF-421E-A766-3D9676D6DE83Q30459163-D38F7A64-BA30-4755-ACD0-DB6E4052F80AQ31983068-2BA2FE26-330D-4107-B17A-9604EECC577DQ33247452-6574D1A3-20B0-4558-B09D-0B6D4896D42FQ33547722-A0CE5A29-7D8A-4F2C-B53D-72AC119B3AC1Q33558752-ACAF3BD2-C2FC-49F8-94B1-8ADD32240176Q33559643-40B4D1EB-DC41-4058-839B-AED22C3E8E97Q33590964-FCC9FA0A-F469-41CC-AB64-DA3871405712Q33805580-BF3BE553-4BDC-4F9D-9099-5121EED32D9FQ34238131-7C8183F2-9FAA-4F92-A928-3C42ECFE5279Q34341256-C0A2EC31-28D8-46DA-9EB1-38E3797538BBQ34433163-251803E3-B046-461C-84A6-812C00BFCF8DQ34501934-D544BC66-58B1-4C4D-9035-C95F31DBF26CQ34628919-357DCE2C-F31F-49AF-9B21-0407F2894813Q35042088-285EC017-EFEB-43C1-9C3D-8D788B2C05E1Q35108533-F89E75E0-8B47-4DE1-9246-8FFDB81C80C5Q35134006-FC6C6ABB-630B-45F9-9062-19CC60F1372FQ35234901-E6845394-CF43-46C1-8EC2-9EFE5AC5865BQ35412202-FDF9D0C6-B400-4045-8465-5685B110D727Q35597530-D9371253-31D1-4ED0-977E-67627E30A06EQ35674966-8E0E7D54-F8C3-4454-A79C-F17E199BCF6FQ35678695-3FFE0C15-255C-4311-99A7-3C712EDC37AAQ35741480-F6C91A29-C583-413B-9D7B-D4345B0BF5EFQ35752919-A60279F0-D037-442B-B165-10C867E54B1DQ36081764-5AA036BD-D491-4044-8515-5821726D86F5Q36117179-FBBD682A-348C-44C8-BFE2-EEB52D474169Q36129275-CC328100-4AAC-41B8-A19E-9A697D247327Q36410337-CFD49CC5-D83B-42C1-8A0A-B8643A3E52E9Q36540080-48467F99-5A2C-4F20-9C5E-8E9E2FB31264Q36544440-08534A58-64E2-4783-BACB-B4923BC89112Q36574152-F8AB478C-0A35-48A3-9A60-1FD2BA644E94Q36609973-F3352B31-A85A-48C0-A6FA-F148D43FC2A7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bradly G Wouters
@nl
Bradly G Wouters
@sl
Bradly G. Wouters
@en
Bradly G. Wouters
@es
Bradly Wouters
@fr
type
label
Bradly G Wouters
@nl
Bradly G Wouters
@sl
Bradly G. Wouters
@en
Bradly G. Wouters
@es
Bradly Wouters
@fr
altLabel
Brad Wouters
@en
prefLabel
Bradly G Wouters
@nl
Bradly G Wouters
@sl
Bradly G. Wouters
@en
Bradly G. Wouters
@es
Bradly Wouters
@fr
P108
P1053
T-1525-2017
P106
P108
P1153
7006091000
P21
P2456
P31
P3829
P496
0000-0002-8187-592X